Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer.

Nature communications·2025

Same author

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

ABBV-303 Is an NK-cell Engager Specific for c-Met-Expressing Tumors.

Cancer research·2025

Same author

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.

Leukemia & lymphoma·2025

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

Protein Engineering by Yeast Surface Display

Protein Engineering by Yeast Surface Display

Published on: November 29, 2024

Engineering higher affinity T cell receptors using a T cell display system.

Adam S Chervin¹, David H Aggen, John M Raseman

¹Department of Biochemistry, University of Illinois, 600 S. Matthews Ave., Urbana, IL 61801, USA.

Journal of Immunological Methods

|October 16, 2008

Summary

This summary is machine-generated.

Researchers engineered a high-affinity T cell receptor (TCR) using a novel T cell display system. This method facilitates the development of TCRs for enhanced adoptive T cell therapies, particularly against tumors.

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Related Experiment Videos

Last Updated: Jun 29, 2026

Protein Engineering by Yeast Surface Display

Protein Engineering by Yeast Surface Display

Published on: November 29, 2024

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Area of Science:

Immunology
Molecular Biology
Biotechnology

Background:

T cell receptor (TCR) affinity for peptide-MHC (pepMHC) dictates cellular responses.
Low-affinity TCRs can limit T cell responses, impacting therapeutic efficacy.
Engineering TCRs for higher affinity is crucial for advancing adoptive T cell therapies, especially for cancer.

Purpose of the Study:

To develop a T cell display system for engineering high-affinity TCRs.
To generate and select a high-affinity TCR from the mouse T cell clone 2C.
To assess the functional capabilities of the engineered TCR in a CD8-independent manner.

Main Methods:

Utilized a retroviral vector-based T cell display system for TCR engineering.
Generated a library within the CDR3alpha region of the 2C TCR.
Employed flow cytometry sorting for selection using a specific pepMHC (SIY/Kb).

Main Results:

Successfully generated a high-affinity TCR from the 2C clone using the T cell display system.
The selected TCR exhibited CD8-independent activity in functional assays.
The engineered TCR contained a CDR3alpha sequence motif similar to those found in TCRs selected via yeast display.

Conclusions:

The T cell display system offers an effective method for isolating and characterizing high-affinity TCRs.
This approach can accelerate the development of TCRs for adoptive T cell therapies.
The generated TCR demonstrates potential for direct use in therapeutic applications without extensive sub-cloning.